This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
== Gameplay == Sven Co-op is a first-person shooter based on Half-Life, using its GoldSrc game engine. The modification enables a server to be hosted, so many players can cooperate (along with any allied non-player characters) to complete levels against creatures and other enemies that are controlled by the computer. The modification was initially based around the levels from Half-Life, but since have expanded to include the other Half-Life games and user-made levels. Multiple levels may be connected to make a longer campaign by the level designer. The game can also be played in single-player mode, taking advantage of improvements over the original Half-Life that were made by the modifications, particularly the artificial intelligence used by non-player characters.
=== Technological industry === In chemical synthesis, products are often freeze-dried to make them more stable, or easier to dissolve in water for subsequent use. In nanotechnology, freeze-drying is used for nanotube purification to avoid aggregation due to capillary forces during regular thermal vaporization drying.
=== Iranian IRGC involvement === In 2013, an Iranian vessel was seized and discovered to be carrying Katyusha rockets, heat-seeking surface-to-air missiles, RPG-7s, Iranian-made night vision goggles and artillery systems that track land and navy targets 40 km away. That was en route to the Houthis. In March 2017, Qasem Soleimani, head of Iran's Quds Force, met with Iran's Islamic Revolutionary Guard Corps (IRGC) regarding the "newly accelerated effort to empower the Houthis", including the provision of weapons and training. Soleimani was quoted as saying, "At this meeting, they agreed to increase the amount of help, through training, arms and financial support." Despite the Iranian government, and Houthis both officially denying Iranian support for the group. Brigadier General Ahmad Asiri, the spokesman of the Saudi-led coalition told Reuters that evidence of Iranian support was manifested in the Houthi use of Kornet anti-tank guided missiles which had never been in use with the Yemeni military or with the Houthis and that the arrival of Kornet missiles had only come at a later time. In the same month the IRGC had altered the routes used in transporting equipment to the Houthis by spreading out shipments to smaller vessels in Kuwaiti territorial waters in order to avoid naval patrols in the Gulf of Oman due to sanctions imposed, shipments reportedly included parts of missiles, launchers, and drugs.
The sponsor designs the trial in coordination with a panel of expert clinical investigators, including what alternative or existing treatments to compare to the new drug and what type(s) of patients might benefit. If the sponsor cannot obtain enough test subjects at one location investigators at other locations are recruited to join the study. During the trial, investigators recruit subjects with the predetermined characteristics, administer the treatment(s) and collect data on the subjects' health for a defined time period. Data include measurements such as vital signs, concentration of the study drug in the blood or tissues, changes to symptoms, and whether improvement or worsening of the condition targeted by the study drug occurs. The researchers send the data to the trial sponsor, who then analyzes the pooled data using statistical tests. Examples of clinical trial goals include assessing the safety and relative effectiveness of a medication or device:
== Research and innovation == BioDuro is involved in developing data-driven and automated workflows intended to accelerate discovery timelines. The company has partnered with technology firms, including Atombeat, to integrate AI-supported peptide-design platforms with high-throughput peptide synthesis and iterative screening workflows. According to the company, these approaches are designed to reduce design–test cycles in peptide and bioconjugate programs; independent evaluation of the platform’s performance is still limited in publicly available literature.
Sources: en.wikipedia.org
Although the condition may remain stable or even regress in many patients, greater severity and recurrence are associated with strong hereditary influence and related fibromatoses, and genetic studies increasingly implicate dysregulated Wnt signaling as an important contributor to disease susceptibility and progression.
SEM images of the radula can be found at Thompson, T.E.; Bebbington, A. (1973). "Scanning electron microscope studies of gastropod radulae". Malacologia. 14: 147–165. Tucker J.K. (2009). Recent cone species database. September 4th 2009 Edition Filmer R.M. (2001). A Catalogue of Nomenclature and Taxonomy in the Living Conidae 1758–1998. Backhuys Publishers, Leiden. 388pp Bouchet, P.; Fontaine, B. (2009). "List of new marine species described between 2002–2006". Census of Marine Life. Natural History Museum Rotterdam - photos of Conus shells Archived 2015-06-09 at the Wayback Machine Cone snail and conotoxins page The Conus Biodiversity website ConoServer Conidae from worldwide.conchology.com. Scroll down for many photographs. Pain-killer comes out of its shell (The Age news article) Venomous snails aid medical science (BBC News Article). ConeShell Collection Giancarlo Paganelli Archived 2019-12-21 at the Wayback Machine Cone Shells - Knights of the Sea. Alexander Medvedev's collection Cone Snail Video - Hunting Footage and Physiology Deadly Critters That Might Save Your Life (CNN) Baldomero "Toto" Olivera's short talk: Conus Peptides Archived 2015-04-06 at the Wayback Machine Zonatus Gallery Miller, John A. (1989). "The toxoglossan proboscis: structure and function". Journal of Molluscan Studies. 55 (2): 167–181. doi:10.1093/mollus/55.2.167. BBC Nature Video Cone snails are silent assassins of the sea, drugging sleeping fish before poisoning them Cone Snail Venom and AI May Lead to Drug Discovery | LANL
As of June 2021, Sputnik V is under rolling review process by EMA, but the marketing authorisation application was not submitted yet. Emergency use has also been authorized in Algeria, Bolivia, Serbia, the Palestinian territories, and Mexico. On 25 January 2021, Iran approved the vaccine, with Foreign Minister Mohammad Javad Zarif saying the country hopes to begin purchases and start joint production of the shot "in the near future", after Supreme Leader Ayatollah Ali Khamenei banned the government from importing vaccines from the United States and United Kingdom. The Czech Republic was also considering buying Sputnik V, and Prime Minister Andrej Babis dismissed the Minister of Health, Jan Blatný, who was a loud opponent to the use of Sputnik V. On 4 March 2021, EMA's human medicines committee (CHMP) has started a rolling review of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine developed by Russia's Gamaleya National Centre of Epidemiology and Microbiology. When asked about the prospect of Austria giving Sputnik V the approval (as some other European countries chose to do), EMA management board chair Christa Wirthumer-Hoche pointed to the fact there was not yet sufficient safety data about those who had already been given the vaccine. "We could have Sputnik V on the market in future, when we've examined the necessary data," she said, adding that the vaccine needed to match up to European criteria on quality control and efficacy.
Bioinformatics ( ) is an interdisciplinary field of science that develops computational methods and software tools for understanding biological data, especially when the data sets are large and complex. Bioinformatics integrates principles from biology, chemistry, physics, computer science, data science, computer programming, information engineering, mathematics, and statistics to analyze and interpret biological data. This process can sometimes be referred to as computational biology; however, the distinction between the two terms is often disputed. The term computational biology can refer to building and using models of biological systems. Some of the main sub-branches of bioinformatics are computational genomics, computational epigenetics, computational immunology, and computational metabolomics. Computational, statistical, and computer programming techniques have been used for computer simulation analyses of biological queries. They include reused specific analysis "pipelines", particularly in the field of genomics, such as by the identification of genes and single nucleotide polymorphisms (SNPs). These pipelines are used to better understand the genetic basis of disease, unique adaptations, desirable properties (especially in agricultural species), or differences between populations. Bioinformatics also includes proteomics, which aims to understand the organizational principles within nucleic acid and protein sequences. Image and signal processing allow the extraction of useful results from large amounts of raw data.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.